Literature DB >> 7987306

Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype.

P A Crossey1, F M Richards, K Foster, J S Green, A Prowse, F Latif, M I Lerman, B Zbar, N A Affara, M A Ferguson-Smith.   

Abstract

Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign neoplasms, most frequently retinal, cerebellar and spinal haemangioblastoma, renal cell carcinoma, phaeochromocytoma and pancreatic tumours. We have previously detected large germline deletions by Southern analysis and pulsed field gel electrophoresis in 19% and 3% of VHL patients respectively. We have now investigated 94 VHL patients without large deletions for intragenic mutations using single strand conformation polymorphism and heteroduplex analysis. Forty different mutations were identified in 55 unrelated kindreds. A wide variety of mutations were detected including missense (n = 19), nonsense (n = 6), frameshift deletions or insertions (n = 12), in frame deletions (n = 2) and a splice donor site mutation (n = 1). The two most frequent mutations, were missense mutations at codon 238 (Arg-->Gln and Arg-->Trp) and were detected in five and four unrelated kindreds, respectively. VHL disease shows marked phenotypic variability and although phaeochromocytoma occurs in only about 7% of patients, marked interfamilial differences are observed. We examined the relationship between VHL gene mutations and phenotype in 65 kindreds. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without phaeochromocytoma but only two of 12 families with phaeochromocytoma (chi 2 = 8.58; P < 0.01). Of 12 families with phaeochromocytoma 10 had missense mutations compared with 13 of 53 kindreds without phaeochromocytoma (chi 2 = 12.33; P < 0.001). In particular, substitution of an arginine at codon 238 (Arg-->Trp or Arg-->Gln) was associated with a high risk (62%) of phaeochromocytoma.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987306     DOI: 10.1093/hmg/3.8.1303

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  80 in total

1.  Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas.

Authors:  H Dannenberg; E J Speel; J Zhao; P Saremaslani; E van Der Harst; J Roth; P U Heitz; H J Bonjer; W N Dinjens; W J Mooi; P Komminoth; R R de Krijger
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Ophthalmic pathology of genotypically confirmed von Hippel Lindau disease type 1.

Authors:  C M Knapp; G Woodruff; F Roberts
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

4.  Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.

Authors:  R Rajasekaran; C Sudandiradoss; C George Priya Doss; Anshuman Singh; Rao Sethumadhavan
Journal:  Mamm Genome       Date:  2008-10-03       Impact factor: 2.957

Review 5.  The von Hippel-Lindau gene: turning discovery into therapy.

Authors:  Peter E Clark; Michael S Cookson
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

6.  Germline mutations in the VHL gene associated with 3 different renal lesions in a Chinese von Hippel-Lindau disease family.

Authors:  Ping Yuan; Qipeng Sun; Hao Liang; Wenjun Wang; Ling Li; Ye Wang; Huan Deng; Luhua Lai; Xiaoli Chen; Xiangfu Zhou
Journal:  Cancer Biol Ther       Date:  2016-04-08       Impact factor: 4.742

7.  Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.

Authors:  Sakari Vanharanta; Mary Buchta; Sarah R McWhinney; Sanna K Virta; Mariola Peçzkowska; Carl D Morrison; Rainer Lehtonen; Andrzej Januszewicz; Heikki Järvinen; Matti Juhola; Jukka-Pekka Mecklin; Eero Pukkala; Riitta Herva; Maija Kiuru; Nina N Nupponen; Lauri A Aaltonen; Hartmut P H Neumann; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-12-18       Impact factor: 11.025

8.  A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.

Authors:  S Cingoz; R B van der Luijt; E Kurt; M Apaydin; I Akkol; Mihriban Heval Ozgen
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

9.  Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect.

Authors:  H Brauch; T Kishida; D Glavac; F Chen; F Pausch; H Höfler; F Latif; M I Lerman; B Zbar; H P Neumann
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

10.  Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH.

Authors:  H J Decker; C Neuhaus; A Jauch; M Speicher; T Ried; M Bujard; H Brauch; S Störkel; M Stöckle; B Seliger; C Huber
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.